News and Analysis
Nature Reviews Drug Discovery 5, 17-18 (January 2006) | doi:10.1038/nrd1933
Fresh from the Pipeline: Nelarabine
Varsha Gandhi1, Michael J. Keating1, Guy Bate2 & Peter Kirkpatrick3
Top of page
Abstract
In October 2005, nelarabine (Arranon; GlaxoSmithKline), a nucleoside analogue, was given accelerated approval by the US FDA for the treatment of patients with T-cell acute lymphoblastic leukaemia and T-cell lymphoblastic lymphoma whose disease has not responded to treatment or has relapsed following treatment with at least two chemotherapy regimens.
Author affiliations
-
Varsha Gandhi and Michael Keating are at the University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston, Texas 77030, USA.
Email: vgandhi@mdanderson.org
Email: mkeating@mdanderson.org -
Guy Bate is at IMS Health, 7 Harewood Avenue, London NW1 6JB, UK.
Email: gbate@uk.imshealth.com -
Peter Kirkpatrick is at Nature Reviews Drug Discovery, UK.
Email: p.kirkpatrick@nature.com
